The type 2 diabetes drug Actos (pioglitazone) is now available as a lower-costing generic. Actos is marketed by Japanese drug maker Takeda Pharmaceuticals. The patent for Actos expires in 2016; however, under the terms of a 2010 legal settlement, generic versions can be marketed as early as August 17, 2012. Both Ranbaxy Laboratories and Teva Pharmaceuticals are now selling generic Actos in three different doses. Another generic drug company, Watson Pharmaceuticals, had hoped to launch a generic version of Actos this week, but the Food and Drug Administration (FDA) has yet to grant the drug final approval. Last week, Watson ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.